[go: up one dir, main page]

NZ600486A - Pirfenidone treatment for patients with atypical liver function - Google Patents

Pirfenidone treatment for patients with atypical liver function

Info

Publication number
NZ600486A
NZ600486A NZ600486A NZ60048609A NZ600486A NZ 600486 A NZ600486 A NZ 600486A NZ 600486 A NZ600486 A NZ 600486A NZ 60048609 A NZ60048609 A NZ 60048609A NZ 600486 A NZ600486 A NZ 600486A
Authority
NZ
New Zealand
Prior art keywords
pirfenidone
administering
liver function
patients
patient
Prior art date
Application number
NZ600486A
Inventor
Williamson Ziegler Bradford
Javier Szwarcberg
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of NZ600486A publication Critical patent/NZ600486A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

600486 Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
NZ600486A 2009-11-09 2009-11-09 Pirfenidone treatment for patients with atypical liver function NZ600486A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ59212209 2009-11-09

Publications (1)

Publication Number Publication Date
NZ600486A true NZ600486A (en) 2014-03-28

Family

ID=50542729

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600486A NZ600486A (en) 2009-11-09 2009-11-09 Pirfenidone treatment for patients with atypical liver function

Country Status (1)

Country Link
NZ (1) NZ600486A (en)

Similar Documents

Publication Publication Date Title
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
UA105191C2 (en) Treatment with pirfenidone of patients with abnormal liver function
PH12014500386A1 (en) Combination treatment for hepatitis c
EP3241840A3 (en) Inhibition of axl signaling in anti-metastatic therapy
IN2014KN00996A (en)
EP2406765A4 (en) Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
HK1221646A1 (en) Use of high dose pridopidine for treating huntington's disease
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ606964A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
NZ600486A (en) Pirfenidone treatment for patients with atypical liver function
NZ597675A (en) Medicament for the long term nsaid use
MD4232B1 (en) Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure
WO2014035828A3 (en) Inhibition of axl signaling in anti-metastatic therapy
UA66406U (en) Method for preventing osteopenic syndrome in pregnant patients with perinatal infection
MD4231B1 (en) Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis
UA48009U (en) Method for treating patients with dysfunction of oddi's sphincter
UA64819U (en) method for treatment of patients with syndrome of irritated bowels, combined with chronic uncalculary cholecystitis and disbiosis
UA89024U (en) Method for complex treatment of ureterolithiasis
MD4458B1 (en) Use of Polybiolin drug in patients with liver cirrhosis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 NOV 2016 BY CPA GLOBAL

Effective date: 20140716

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2017 BY CPA GLOBAL

Effective date: 20160923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2018 BY CPA GLOBAL

Effective date: 20171005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2019 BY CPA GLOBAL

Effective date: 20180927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2020 BY CPA GLOBAL

Effective date: 20191003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2021 BY CPA GLOBAL

Effective date: 20200924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2022 BY CPA GLOBAL

Effective date: 20211007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2023 BY CPA GLOBAL

Effective date: 20221007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2024 BY CPA GLOBAL

Effective date: 20231006

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241011

ASS Change of ownership

Owner name: F. HOFFMAN-LA ROCHE AG, NZ

Effective date: 20250124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251010